Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Johnson and Johnson
Merck
Harvard Business School
McKesson

Last Updated: June 3, 2023

CLINICAL TRIALS PROFILE FOR RIBAVARIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ribavarin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00502970 ↗ Short Course of Interferon Treatment in Patients With HCV Infection Completed Getz Pharma Phase 4 2004-05-01 To determine if a shorter course of interferon and ribavirin therapy will be sufficient in carefully selected patients with chronic hepatitis C virus genotype 3 infection, as compared to the standard length of treatment of 6 months.
NCT00502970 ↗ Short Course of Interferon Treatment in Patients With HCV Infection Completed Aga Khan University Phase 4 2004-05-01 To determine if a shorter course of interferon and ribavirin therapy will be sufficient in carefully selected patients with chronic hepatitis C virus genotype 3 infection, as compared to the standard length of treatment of 6 months.
NCT00703872 ↗ HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients Unknown status Hepasome Pharmaceuticals Phase 2 2008-05-01 A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic Response (RVR)] and safety as the reported efficacy and safety with pegylated alpha-interferon-2a and ribavirin (historical control) in patients with chronic hepatitis C (treatment na├»ve by oral route and non-responders by SC route respectively).
NCT00842205 ↗ Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection Unknown status IGA MZ, Czech Republic N/A 2007-01-01 In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied. Heme oxygenase expression will be evaluated by the techniques of molecular genetics and immunohistochemistry, both in the liver tissue and in peripheral blood mononuclear cells. These parameters will be correlated with basic virological and clinical characteristics of the chronic HCV infection. The investigators' expected results may help in understanding the mechanisms of fibroproduction in chronic HVC infection and, therefore, contribute to explain individual differences in the development of chronic HCV infection.
NCT00842205 ↗ Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection Unknown status Charles University, Czech Republic N/A 2007-01-01 In the presented project, the role of heme oxygenase 1 and 2 in the procesess associated with fibroproduction in the chronic HCV infection will be studied. Heme oxygenase expression will be evaluated by the techniques of molecular genetics and immunohistochemistry, both in the liver tissue and in peripheral blood mononuclear cells. These parameters will be correlated with basic virological and clinical characteristics of the chronic HCV infection. The investigators' expected results may help in understanding the mechanisms of fibroproduction in chronic HVC infection and, therefore, contribute to explain individual differences in the development of chronic HCV infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ribavarin

Condition Name

Condition Name for Ribavarin
Intervention Trials
Hepatitis C 4
Treatment 1
Chronic Disease 1
Chronic HCV Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ribavarin
Intervention Trials
Hepatitis C 6
Hepatitis 5
Hepatitis A 3
Thalassemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ribavarin

Trials by Country

Trials by Country for Ribavarin
Location Trials
India 1
Lebanon 1
Pakistan 1
United States 1
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ribavarin
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ribavarin

Clinical Trial Phase

Clinical Trial Phase for Ribavarin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ribavarin
Clinical Trial Phase Trials
Completed 4
Unknown status 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ribavarin

Sponsor Name

Sponsor Name for Ribavarin
Sponsor Trials
GlaxoSmithKline 2
ViiV Healthcare 1
Merck Sharp & Dohme Corp. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ribavarin
Sponsor Trials
Industry 8
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Dow
Harvard Business School
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.